Oncology & Cancer

Study drug LOXO-101 shows tumor regression in varied cancers

A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.

Oncology & Cancer

Killer cocktail fights brain cancer

A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

Oncology & Cancer

RNA regulator of melanoma could be a new target for cancer therapy

Melanoma is the most deadly form of skin cancer, estimated by the National Cancer Institute to afflict more than 70,000 people in the United States annually and the incidence rate continues to rise. In a study published online ...

page 2 from 3